LG – Lead Generation
LO – Lead Optimization
P1 – Phase 1
P2 – Phase 2
AMR - ANTIBACTERIAL
BWC0977
IV + Oral step down small molecule agent for treating critical care infections
GYROX NXTGEN
IV + Oral step down small molecule agent for treating critical care and community infections
Coverage:
- Critical priority pathogens including carbapenem resistant Enterobacteriaceae, Acinetobacter baumannii & Pseudomonas aeruginosa
- High priority pathogens including Enterococcus faecium, Staphylococcus aureus, Campylobacter sp., Streptococcus pneumoniae
- Bio-threat pathogens including Bacillus anthracis, Yersinia pestis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei
ONCOLOGY
BWC2094
A2AR/A2BR/ENT1
Coverage:
- Adenosine-axis biology implicated across immunologically suppressed solid tumours including CRC, NSCLC, TNBC, pancreatic, prostate, RCC, HNSCC and ovarian cancers.
- Potential first-in-class small-molecule approach targeting multiple nodes of the adenosine pathway.
- Potential combination with immune checkpoint inhibitors, cytotoxics, targeted therapies and cell-based therapies.
- Designed to address immune suppression, tumour microenvironment resistance and poor response to existing immuno-oncology therapies.
BWC5681 / BWC6388
CDK7/2
Coverage:
- Dual transcription and cell-cycle control strategy for aggressive, transcription-addicted and replication-stress driven tumours.
- Potential relevance in TNBC, ovarian, prostate, lung and MYC/CCNE-driven cancers.
- CDK2 component may address cyclin-E/CDK2 driven resistance biology.
- Potential combination with endocrine therapy, chemotherapy, DDR agents and targeted therapies.
BWC6323 / BWC6362
CDK7/9
Coverage:
- Transcriptional dependency approach targeting cancers reliant on CDK7/CDK9-mediated oncogenic transcription.
- Potential relevance in MYC-driven, MCL1-dependent and transcriptionally addicted solid tumours.
- May support activity in cancers resistant to conventional cell-cycle or targeted therapies.
- Potential combination with apoptosis modulators, chemotherapy and immune-oncology agents.
BWC6096 / BWC6389
CDK7
Coverage:
- CDK7 inhibition for transcriptionally addicted and difficult-to-treat tumours.
- Potential relevance in TNBC, ovarian, prostate, lung and GI cancers.
- Opportunity to modulate oncogenic transcription and cell-cycle progression through a targeted small-molecule approach.
- Potential use in biomarker-selected tumours and rational combinations with DDR, IO and cytotoxic regimens.
BWC6135 / BWC6151
PARP1
Coverage:
- Targeting DNA damage repair vulnerabilities across BRCA-mutant, HRD-positive and replication-stress driven tumours.
- Potential relevance in ovarian, breast, prostate, pancreatic and selected GI cancers.
- Selective PARP1 approach may support differentiation versus earlier PARP inhibitors.
- Potential for combinations with DDR agents, chemotherapy, radiotherapy and immune-oncology regimens.
BWC6305 / BWC6414
PIK3CA/ATM/DNA-PK
Coverage:
- Multi-node targeting of PI3K and DNA damage response pathways.
- Potential relevance in PIK3CA-mutant, DDR-deficient and radio/chemo-resistant solid tumours.
- Coverage may include breast, ovarian, endometrial, prostate, lung, head & neck and GI cancers.
- Strong potential for combination with radiotherapy, chemotherapy, PARP inhibitors and immune-oncology agents.
BWC5167 / BWC5197
Splicing Modulator
Coverage:
- Targeting aberrant RNA splicing and spliceosome dependency in cancer.
- Potential relevance in tumours with splicing-factor alterations, high transcriptional stress or difficult-to-drug oncogenic programs.
- Coverage may include hematologic malignancies and selected solid tumours.
- Potential directed cytotoxic opportunity, including payload-like applications and combination with targeted therapies.
BWC5820 / BWC5847
PTPN1/PTPN2
Coverage:
- Immuno-oncology target designed to enhance anti-tumour immune signalling.
- Potential relevance across immune-resistant solid tumours including melanoma, lung, renal, colorectal and head & neck cancers.
- May improve interferon/JAK-STAT signalling and tumour immune recognition.
- Strong combination potential with checkpoint inhibitors, cytokine-based approaches and cell therapies.
BWC4221 / BWC3416
MAT2A Inhibitor
Coverage:
- Synthetic-lethal strategy targeting MTAP-deleted cancers through MAT2A dependency.
- Potential relevance in pancreatic, lung, bladder, glioblastoma, mesothelioma and selected GI cancers where MTAP loss is observed.
- Biomarker-led opportunity with clear patient-selection logic.
- Potential combination with PRMT5-pathway agents, chemotherapy and targeted therapies.
Partners
